A very positive result; let’s hope that this drug can at minimum provide the patients and thier families with a way to stabilise the disease a5 minimum. Really hope the6 allow compassionate use for those that wish to accept the risk of using an early stage drug that has not. completed phase 2b and phase 3 testing.
Ann: Trial Met Primary & Exceeded Secondary Endpoint Expectations, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.8¢ |
Change
-0.001(5.88%) |
Mkt cap ! $8.699M | |||
| Open | High | Low | Value | Volume |
| 0.8¢ | 0.8¢ | 0.8¢ | $2.01K | 251.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 4817091 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 1969872 | 4 |
View Market Depth
| Last trade - 15.47pm 04/07/2025 (20 minute delay) ? |
| PER (ASX) Chart |